A coalition of researchers and advocates met in Washington this week after autism scientists from rival research panels became one of the clearest signs yet of growing resistance to the Trump administration’s reshaping of federal autism policy.
The new body, called the Independent Autism Coordinating Committee, held its first meeting as a science-focused alternative to the federal Interagency Autism Coordinating Committee, or IACC, which Health Secretary Robert F. Kennedy Jr. overhauled in January.
The timing was deliberate. The independent panel had planned to meet the same week as the federal committee’s first public session under Kennedy’s new membership, but that government meeting was canceled without explanation.
That cancellation added to concerns among autism researchers and patient advocates who say the federal panel is drifting away from established science and toward ideological battles, including revived attention to the debunked claim that vaccines cause autism.
Kennedy’s Overhaul Triggered a Backlash
The federal IACC has long helped shape priorities for federally funded autism research. On January 28, 2026, HHS announced 21 new members for the committee, describing the move as part of Kennedy’s effort to align autism research with what the department called “gold-standard science.”
Critics saw something else. They argued that the new roster reduced scientific independence and opened the door to members who echo Kennedy’s long-running skepticism of vaccine safety.
That backlash pushed former advisers, scientists, and advocacy leaders to organize outside government. The new independent panel said it wants to provide a science-based guide to autism research priorities and to counter what members view as misinformation and politicization. The group does not control federal grants or official recommendations, but many of its members hold influence in major research and advocacy networks, which gives it weight even without formal government authority.
The Fight Is Also About What Autism Research Should Study
The independent committee’s early discussions focused on research priorities rather than political theater.
Coverage of the inaugural meeting said members discussed genetic biomarkers, co-occurring conditions, early detection, and the needs of autistic people who have little or no spoken language and require higher levels of support. The panel also signaled that it wants to keep research grounded in evidence and in the lived experiences of autistic people and their families.
At the same time, the new group has drawn its own criticism. Some autistic advocates told The Guardian they worry that neither the federal committee nor the independent alternative includes enough autistic representation.
Others object to the use of terms such as “profound autism,” arguing that they can oversimplify a broad spectrum of needs and experiences. That means the debate is not only about Kennedy or vaccines. It is also about who gets to define autism research, which questions receive funding, and whose voices count in setting that agenda.
A Broader Struggle Over Science and Public Trust
The Washington meeting fits a wider pattern in U.S. health policy under Kennedy. Scientists and medical groups have already challenged other changes made under his leadership, including revisions to vaccine policy and advisory board shake-ups.
In that context, the emergence of a rival autism panel shows how some researchers now see outside organizing as necessary when they believe federal structures no longer protect scientific standards.
For now, the Independent Autism Coordinating Committee remains unofficial. It cannot replace the federal IACC, nor can it direct public funds. But its formation still matters. By convening in Washington and staking out a public role, the group is trying to shape the research conversation before federal priorities harden around disputed ideas.
As a result, the fact that autism scientists form a rival research panel is not just a headline about one meeting. It is a sign of a deeper struggle over evidence, representation, and who will define autism science in the United States.